Miruvor
Sign up
The short answer

What studies of CBD (cannabidiol) found

3papers on CBD (cannabidiol)
24people in 2 studies testing CBD (cannabidiol) alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, the randomised trial and studies with no comparison group (very low certainty): 2 of 3 findings are C.

2 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: CBD (cannabidiol) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 3 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. CBD (cannabidiol) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Sleep1 study · 12 people took CBD (cannabidiol) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (12 in all); not all results were tested against chance.

Studies with no comparison group12 in the study · 6 months (24 weeks) · "up to 3 mL of MediCabilis 5% CBD Oil (50 mg CBD/mL, <2 mg δ-9-tetrahydrocannabinol/mL) per day"; maximum "3 mL (150 mg CBD, <6 mg THC)", "The treatment phase of the study drug was for a total of 21 weeks. There was an initial titration period of 15 days whereby participants were titrated up to a maximum daily dose of 2 mL (100 mg CBD, <4-mg THC)."

Sleep improved.

The evidence is very uncertain about the effect of CBD (cannabidiol) on sleep in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (12 in all)
  • Not all results were tested against chance
See the 1 study
  1. Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial. (2024)

    People in the study
    12 in the study
    Dose
    "up to 3 mL of MediCabilis 5% CBD Oil (50 mg CBD/mL, <2 mg δ-9-tetrahydrocannabinol/mL) per day"; maximum "3 mL (150 mg CBD, <6 mg THC)", "The treatment phase of the study drug was for a total of 21 weeks. There was an initial titration period of 15 days whereby participants were titrated up to a maximum daily dose of 2 mL (100 mg CBD, <4-mg THC)."
    Outcome
    Sleep scores
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms2 studies · 24 people took CBD (cannabidiol) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 24 people found no clear difference; a small benefit can't be ruled out.

The randomised trial24 analysed · 28 days Treatment Period 1; 28 days Treatment Period 2 · 0.25 mL, 28 days blinded active

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of CBD (cannabidiol) on overall symptoms in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 24 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group12 in the study · 6 months (24 weeks) · "up to 3 mL of MediCabilis 5% CBD Oil (50 mg CBD/mL, <2 mg δ-9-tetrahydrocannabinol/mL) per day"; maximum "3 mL (150 mg CBD, <6 mg THC)", "The treatment phase of the study drug was for a total of 21 weeks. There was an initial titration period of 15 days whereby participants were titrated up to a maximum daily dose of 2 mL (100 mg CBD, <4-mg THC)."

Overall symptoms improved.

The evidence is very uncertain about the effect of CBD (cannabidiol) on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (12 in all)
  • Not all results were tested against chance
See the 2 studies
  1. A Single-Blind, Randomized, Placebo Controlled Study to Evaluate the Benefits and Safety of Endourage Targeted Wellness Formula C Sublingual +Drops in People with Post-Acute Coronavirus Disease 2019 Syndrome. (2024)

    People in the study
    24 analysed
    Dose
    0.25 mL, 28 days blinded active
    Outcome
    Patient global impression of change
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial. (2024)

    People in the study
    12 in the study
    Dose
    "up to 3 mL of MediCabilis 5% CBD Oil (50 mg CBD/mL, <2 mg δ-9-tetrahydrocannabinol/mL) per day"; maximum "3 mL (150 mg CBD, <6 mg THC)", "The treatment phase of the study drug was for a total of 21 weeks. There was an initial titration period of 15 days whereby participants were titrated up to a maximum daily dose of 2 mL (100 mg CBD, <4-mg THC)."
    Outcome
    Several aspects of health
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported6 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Anxiety or irritability1 study
Dizziness1 study
Headache1 study
Nausea or stomach upset1 study
Trouble sleeping1 study
Vivid dreams or nightmares1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    2 mg at the start

  2. 2Raise

    Raised step by step in 1 of 1 studies

  3. 3Top dose

    Most often 150 mg (1 of 1 studies)

Doses across 1 study

2 to 150 mg.

Each study’s dose, as printed

All papers

  1. A Single-Blind, Randomized, Placebo Controlled Study to Evaluate the Benefits and Safety of Endourage Targeted Wellness Formula C Sublingual +Drops in People with Post-Acute Coronavirus Disease 2019 Syndrome.2024 · randomised trial · 24 analysed
    Summary

    This randomized, placebo-controlled, single-blind, open-label crossover study enrolled adults with Post-Acute Coronavirus Disease 2019 Syndrome (PACS), recruited through an IRB-approved study flyer at post-COVID treatment centers. Group 1 (n = 15) received blinded Formula C, a CBD-rich whole-flower preparation, for 28 days; Group 2 (n = 16) received blinded placebo for 28 days. Both groups then crossed over to open-label active product for 28 days, with a safety assessment at day 70. PROMIS and PGIC scores were measured at day 0, day 28, and day 56. Twenty-four participants completed, with 8 withdrawals, none related to study product. In Group 1, dyspnea, anxiety, and sleep disturbance improved at day 28 (p = 0.013, 0.006, and 0.041); anxiety and sleep disturbance effects held at day 56 (p < 0.009 and p < 0.021). Group 2 showed improvements in anxiety, dyspnea, depression, fatigue, sleep disturbance, and pain, but none reached statistical significance; anxiety and dyspnea were marginally significant with p < 0.1. PGIC improved in both groups, and the paper states no benefit of Group 1 compared with Group 2 between day 0 and day 28. One Group 2 participant withdrew due to lightheaded sensation and euphoria, assessed by the investigator as not related to study product. The placebo was later found to contain therapeutic levels of terpenes, so the study continued without a true placebo.

  2. Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.2024 · no comparison group · 12 in the study
    Summary

    This single-arm, open-label phase 2 feasibility trial enrolled 12 adults with a clinical diagnosis of long COVID (from a planned 30) in Yorkshire, north of England. Participants received oral MediCabilis 5% CBD Oil, up to 3 mL (150 mg CBD, <6 mg THC) per day. The treatment phase lasted 21 weeks within a 6-month (24-week) study period. There was no comparison group. Monthly patient-reported outcomes, daily symptom reports via a smartphone app and Fitbit measures of heart rate, activity, sleep and oxygen saturation were collected; adverse events and side effects were recorded. The trial reported 100% retention; 11 participants reached the maximum daily dose of 3 mL, while 1 reached 1 mL, reduced and maintained at 0.7 mL. No serious adverse events were reported. A total of 22 adverse events were reported by 11 participants (18 mild, 4 moderate), and 145 side effects were reported. Dry mouth was reported by 11 participants, increased appetite by 9 and dry/itchy eyes by 9; deterioration of long COVID symptoms by 7, with 5 after tapering; Fitbit allergy/irritation by 3. Secondary analyses were exploratory: potential trends in improvements in anxiety, depression and sleep scores at month 3 and 4 were observed, with no apparent trends in Fitbit data; possible reduction in sleep after tapering and worsening of some measures at the end of study were noted. The authors stated limitations included the open-label design, no placebo control, small self-selecting sample, recruitment lower than expected, geographic constraints and supply issues.

  3. Systematic review of interventions for mental health, cognition and psychological well-being in long COVID.2024 · systematic review
    Summary

    This systematic review aimed to identify and synthesise publicly available research testing treatments for mental health, cognition and psychological well-being in long COVID. It included 33 documents representing 31 studies and 2477 participants recruited across four continents. The studies covered 7 psychosocial, 5 pharmaceutical, 3 natural supplement, 9 neurocognitive, 2 physical rehabilitation and 5 integrated intervention studies; 11 were RCTs, 2 non-randomised controlled trials, 10 uncontrolled trials, 7 case studies or series and 1 qualitative study. Some controlled trials reported significant group×time interactions: vortioxetine for depression and health-related QoL but not cognition; hyperbaric oxygen for total cognition and psychological distress only; high-definition transcranial direct current stimulation for cognitive and psychosocial fatigue, anxiety and QoL; and a programme combining non-invasive cognitive stimulation and guided mindfulness for mental fatigue, anxiety, depression, mood disturbance and several cognitive domains. Other trials reported no significant group×time interaction, including an adaptogen formulation and the ReCOVERY app. Many uncontrolled studies reported significant prepost improvements, but the authors state these cannot be definitively associated with treatment without a control group. Counts of people who worsened or stopped and side-effect counts were not reported in the recorded data; the authors note many studies did not report adverse events.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime